Claims for Patent: 10,047,163

Summary for Patent: 10,047,163

Title:	Multispecific constructs
Abstract:	Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions.
Inventor(s):	Liu; David (San Francisco, CA)
Assignee:	AbbVie Stemcentrx LLC (North Chicago, IL)
Application Number:	14/765,861
Patent Claims:	1. A bispecific bivalent antibody comprising a first binding region having a first CL domain comprising a S176K and N137K or N137R mutation, and a first CH1 domain comprising a S188D and T192D mutation; and a second binding region having a second CL domain comprising a S176D and N137D mutation and a second CH1 domain comprising a S188K and T192K mutation wherein the residues are numbered according to Kabat. 2. The bispecific bivalent antibody of claim 1 wherein said antibody further comprises a cytotoxic agent. 3. The bispecific bivalent antibody of claim 1 comprising a first binding region and a second binding region wherein said first and second binding region each comprise a light chain variable region and a heavy chain variable region from an antibody selected from the group consisting of abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farletuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, narnatumab, naptumomab, necitumumab, nimotuzumab, nofetumomabn, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, simtuzumab, solitomab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, and CC49, wherein the first and second binding regions are from different antibodies.

Details for Patent 10,047,163

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,047,163	2034-02-07
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	10,047,163	2034-02-07
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	10,047,163	2034-02-07
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	10,047,163	2034-02-07
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	10,047,163	2034-02-07
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	October 12, 2004	10,047,163	2034-02-07
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	February 12, 2004	10,047,163	2034-02-07

International Patent Family for US Patent 10,047,163

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2014124326
United States of America	2015368352
Japan	2016509014
Hong Kong	1218930
European Patent Office	2954056
Canada	2900764